<DOC>
	<DOCNO>NCT02534779</DOCNO>
	<brief_summary>This open-label study examine disintegration/disappearance time , safety , acceptability placebo vaginal insert . Participants use placebo vaginal insert twice : first in-clinic disintegration/safety assessment , second time at-home acceptability assessment , safety assess follow clinic visit .</brief_summary>
	<brief_title>Assessing Disintegration , Safety , Acceptability Placebo Vaginal Inserts Delivery Vaginal Products</brief_title>
	<detailed_description>This open-label study examine disintegration/disappearance time , safety , acceptability placebo vaginal insert . Participants use placebo vaginal insert twice : first in-clinic disintegration/safety assessment , second time at-home acceptability assessment , safety assess follow clinic visit . Participants assign test insert either follicular luteal phase menstrual cycle , number woman test follicular phase approximately equal number test luteal phase . Once eligibility confirm , participant complete in-clinic disintegration test estimate amount time require disintegration complete disappearance vaginal insert . Prior follow disintegration test , participant pelvic exam vaginal swab ( ) collect development adherence measure . Safety assess naked eye exam report adverse event ( AEs ) . 24 72 hour follow in-clinic disintegration test , participant use vaginal insert home complete standardize acceptability questionnaire 4 hour 24 hour placement . The acceptability questionnaire return clinic participant 's next visit . The final clinic visit schedule 24-72 hour placement vaginal insert use home . The final study visit include pelvic exam ass safety vaginal swab ( ) collect development adherence measure . The participant exit study follow final study visit . This study design test single placebo vaginal insert , possible additional insert may become available test . Participants may re-enroll study test additional vaginal insert become available .</detailed_description>
	<mesh_term>Vaginal Diseases</mesh_term>
	<criteria>Age 1850 year , inclusive General good health ( volunteer history investigator judgment ) Currently regular menstrual cycle 21 35 day volunteer report Protected pregnancy , mean one following : Sexually abstinent plan remain abstinent duration study ; In monogamous heterosexual relationship least four month partner know HIV positive know risk sexually transmit infection ( STIs ) : Couple use condom willing use nonspermicidally lubricate condom throughout study One partner sterilize ; monogamous samesex relationship least four month partner know HIV positive know risk STIs . Willing abstain vaginal activity vaginal product use require protocol Vaginal cervical anatomy , opinion investigator , lend easy examination Willing give voluntary consent , sign inform consent form comply study procedure require protocol History hysterectomy Currently pregnant within two calendar month last pregnancy outcome . Note : If recently pregnant must least two spontaneous menses since pregnancy outcome Use hormonal contraceptive method last 30 day ( oral , transdermal , transvaginal , implant , hormonal intrauterine contraceptive device ) Injection DepoProvera last 6 month Current use copper intrauterine device ( IUD ) Currently breastfeed breastfed infant last two month , plan breastfeed course study History sensitivity/allergy component study product Symptomatic reproductive tract infection ( RTI ) Chronic acute vulvar vaginal symptom ( pain , irritation , spot , etc . ) Known current drug alcohol abuse could impact study compliance Participation investigational trial ( device , drug , vaginal trial ) within last 30 day plan participation investigational trial study History gynecological procedure ( include genital piercing ) external genitalia , vagina cervix within last 14 day Abnormal find physical examination social medical condition , opinion investigator , would make participation study unsafe would complicate interpretation data</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>